Intelligence is defined as the ability to learn. The Voyant Intelligent Energy system is the advanced energy solution with the ability to accelerate learning from live human tissue. Through gaining insights from our devices in use, Applied Medical continues to advance the Voyant technology to better meet specific clinical needs.


The Voyant system’s continual energy optimization means Applied Medical can make each activation more efficient resulting in superior hemostasis,* faster seal times, minimal lateral thermal spread, and less tissue adherence. It means the technology has the potential to address energy delivery for even the most challenging tissue types.

The efficiency of the latest advancement of the Voyant system has resulted in seal times of less than one second. Each handpiece has shown a substantial reduction in sealing time without compromising hemostasis. As a result, over 95% of survey responses stated a belief that the sealing speed of the Voyant system can contribute to a reduction in procedural time compared to other advanced energy devices.§


The Voyant device key connected to every handpiece stores activation data from each vessel or tissue bundle sealed throughout the procedure. By partnering with hospitals and surgeons to collect device keys, Applied Medical scientists and engineers are able to analyze the data to further optimize energy delivery. In this way, Applied Medical is able to learn and advance our technology, continuing the company’s proven track record of listening to the customer and continuously updating our devices to better meet ever-changing healthcare needs.


Loading the player...


Brochure | Voyant Intelligent Energy System

Portfolio | Voyant Value Analysis Portfolio

Specifications | Voyant Intelligent Energy System


Products may not be approved for distribution in all markets.
Please contact your Field representative for availability.

* Unpublished test reports compared with the data of a leading advanced bipolar device. February and March 2021 benchtop testing using ex vivo porcine tissue.
Based on an unpublished test report from April 2020, comparing the current algorithm to the previous algorithm. Benchtop testing was conducted using ex vivo porcine tissue.
Based on unpublished H&E histological analysis performed in April 2020, comparing the current algorithm to the previous algorithm. Testing was conducted using in vivo porcine tissue.
§ Surgeon feedback collected from EB215, EB210, EB230 and EB240 cases in 2020 and 2021, comparing the current algorithm to the previous algorithm.